Enovis (NYSE: ENOV) today reported fourth-quarter financial results that came in mixed compared to the consensus forecast.
Shares of ENOV fell 2.5% to $22.32 apiece in pre-market trading today.
The Dallas-based company reported losses of $520.6 million. That equals $9.10 per share on sales of $575.8 million for the three months ended Dec. 31, 2025. Fourth-quarter results reflected growth in Global Reconstructive and stable execution in Prevention & Recovery.
Enovis — one of the largest orthopedic device companies in the world — recorded a 26% bottom-line gain on a sales increase of 24.3%. The company notes that the losses included a $501 million non-cash goodwill impairment charge after evaluating the company’s stock price and market capitalization relative to the carrying value of its Reconstructive and P&R reporting units.
Adjusted to exclude one-time items, earnings per share came in at 95¢. That landed 11¢ ahead of expectations on Wall Street. However, sales fell shy of the forecast for $582.4 million in revenue.
Enovis expects 2026 revenue to land between $2.31 billion and $2.37 billion, marking 4%-6% organic growth. It anticipates full-year adjusted EPS to range between $3.52 and $3.73.
“Our 2025 performance reflects a year of meaningful operational progress for the company. We advanced our second-year Lima integration priorities, operated effectively in a dynamic global environment, and continued to demonstrate above-market organic growth with sustainable year-over-year operating improvements which included positive free cash flow and debt reduction,” said Damien McDonald, Enovis CEO. “As we enter 2026, our focus remains consistent and disciplined — driving commercial execution, advancing our rich innovation pipeline, improving operational efficiency, and maintaining financial discipline — as we position the company for durable, capital-efficient growth while remaining attentive to the evolving macro environment.”
